Evidence map›Paper›PMID 31836406›Full record

ArticleThe Journal of allergy and clinical immunology2020

Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies.

Marat V Khodoun, Suzanne C Morris, Elizabeth Angerman, Crystal Potter, Richard Schuman, Mark Wunderlich, Joseph J Maciag, Kathryn C Sullivan Locker, James C Mulloy, Andrew B Herr and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Importance of mast cell histamine secretion in IgG-mediated systemic anaphylaxis.The Journal of allergy and clinical immunology · 2025
    Article
  2. Review
  3. Review
  4. Optimizing drug inhibition of IgE-mediated anaphylaxis in mice.The Journal of allergy and clinical immunology · 2022
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Marat V KhodounDivision of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Suzanne C MorrisDivision of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Elizabeth AngermanDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Crystal PotterDivision of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Richard SchumanAntibody and Immunoassay Consultants, LLC, Rockville, Md.
Mark WunderlichDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Joseph J MaciagDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Kathryn C Sullivan LockerDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
James C MulloyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Andrew B HerrDivision of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Fred D FinkelmanDivision of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: finkelfd@ucmail.uc.edu.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati Medical Center · US

Funding

Rapid, safe suppression of IgE-mediated disease with monovalent anti-ceRIa mAbR01AI145991 · NIAID · UNIVERSITY OF CINCINNATI · PI FINKELMAN, FRED DOUGLASS, KHODOUN, MARAT · 2019 to 2023
$2.6M
Therapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9M
Suppression of IgE-Mediated Disease by Polyclonal Rapid DesensitizationR01AI113162 · NIAID · UNIVERSITY OF CINCINNATI · PI FINKELMAN, FRED DOUGLASS · 2014 to 2017
$1.6M
NCI NIH HHS R50 CA211404NIAID NIH HHS R01 AI113162NIAID NIH HHS R01 AI145991
6 · The paper itself

Abstract

backgroundAnaphylaxis is classically mediated by allergen cross-linking of IgE bound to the α chain of FcεRI, the mast cell/basophil high affinity IgE receptor. Allergen cross-linking of the IgE/FcεRI complex activates these cells, inducing release of disease-causing mediators, cytokines, and enzymes. We previously demonstrated that IgE-mediated anaphylaxis could be safely prevented in wild-type BALB/c mice by rapid desensitization with anti-mouse FcεRIα mAb.

objectiveThis study sought to use humanized mice to extend these results to humans.

methodsWe actively immunized huFcεRIα/F709 mice, which express human (hu) instead of mouse FcεRIα and a mutant IL-4 receptor that lacks inhibitory function. We passively immunized huFcεRIα mice, as well as human cord blood-reconstituted reNSGS mice, which are immune-deficient, produce mast cell-stimulating human cytokines, and develop numerous human mast cells. For desensitization, we used anti-huFcεRIα mAbs that bind FcεRIα regardless of its association with IgE (noncompeting mAbs), and/or mAbs that compete with IgE for huFcεRIα binding (competing mAbs). Anaphylaxis was induced by intravenous injection of antigen or anti-huIgE mAb.

resultsAnti-huFcεRIα mAb rapid desensitization was safer and more effective than allergen rapid desensitization and suppressed anaphylaxis more rapidly than omalizumab or ligelizumab. Rapid desensitization of naïve, IgE-sensitized huFcεRIα mice and huFcεRIα/F709 mice that were egg-allergic with anti-FcεRIα mAbs safely removed >98% of IgE from peritoneal mast cells and completely suppressed IgE-mediated anaphylaxis. Rapid desensitization of reNSGS mice with anti-FcεRIα mAbs also safely removed ∼98% of mast cell IgE and prevented IgE-mediated anaphylaxis.

conclusionsRapid desensitization with anti-FcεRIα mAbs may be a safe, effective, and practical way to prevent IgE-mediated anaphylaxis.

Indexed as

AnaphylaxisAnimalsAntibodies, MonoclonalDesensitization, ImmunologicHumansMiceMice, Inbred BALB CReceptors, IgEAntibodies, MonoclonalFcepsilonRI alpha-chain, humanReceptors, IgEAnaphylaxisantibodyIgEmouse

Identifiers

PMID31836406
PMCPMC7607676
OpenAlexW2996647126

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.